AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10202315 — intervention group
Group type: EXPERIMENTAL
Intervention: Theolong 400 mg/day
Number of subjects: 24
Study 7771486 — intervention group
Group type: EXPERIMENTAL
Intervention: High blood flow (400 mL/min) for 2 hours with cuprophan membrane
Number of subjects: 17
Study 7771486 — intervention group
Group type: EXPERIMENTAL
Intervention: High blood flow (400 mL/min) for 2 hours
Number of subjects: 17
Study 2250630 — intervention group
Group type: EXPERIMENTAL
Intervention: flunisolide + salbutamol
Number of subjects: 18
Study 2250630 — intervention group
Group type: COMPARATOR
Intervention: salbutamol
Number of subjects: 18
Study 6116855 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP + P vaccine (with pertussis adjuvant)
Number of subjects: 64
Study 6116855 — intervention group
Group type: COMPARATOR
Intervention: PRP vaccine alone
Number of subjects: 64
Study 30325270 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body wearable resistance (LB) 5% body mass (BM)
Number of subjects: 12
Study 30325270 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable resistance (1-10% BM)
Number of subjects: 12
Study 30325270 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable resistance (5% BM and greater)
Number of subjects: 12
Study 29226471 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenderitide (4-hour infusion)
Number of subjects: 0
Study 27382808 — intervention group
Group type: EXPERIMENTAL
Intervention: Storz DCI® video laryngoscopy
Number of subjects: 65
Study 27382808 — intervention group
Group type: COMPARATOR
Intervention: Direct laryngoscopy
Number of subjects: 65
Study 27382808 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope Cobalt® video laryngoscopy
Number of subjects: 65
Study 27382808 — intervention group
Group type: EXPERIMENTAL
Intervention: All laryngoscopes
Number of subjects: 65
Study 25197997 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium Hydroxide (CH) with Sodium Hypochlorite (NaOCl)
Number of subjects: 128
Study 25197997 — intervention group
Group type: COMPARATOR
Intervention: Calcium Hydroxide (CH) with Saline (control)
Number of subjects: 128
Study 25197997 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate (MTA) with Sodium Hypochlorite (NaOCl)
Number of subjects: 128
Study 25197997 — intervention group
Group type: COMPARATOR
Intervention: Mineral Trioxide Aggregate (MTA) with Saline (control)
Number of subjects: 128
Study 22231479 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (1,000 mg)
Number of subjects: 144
Study 22231479 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 22231479 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 144
Study 19553088 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term psychodynamic psychotherapy (SPP)
Number of subjects: 326
Study 19553088 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term psychodynamic psychotherapy (LPP)
Number of subjects: 326
Study 19553088 — intervention group
Group type: EXPERIMENTAL
Intervention: Solution-focused therapy (SFT)
Number of subjects: 326
Study 19553088 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 326
Study 17593074 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (4 g daily for 10 days)
Number of subjects: 0
Study 17593074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15942808 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyber visual training (Group C)
Number of subjects: 36
Study 15942808 — intervention group
Group type: COMPARATOR
Intervention: Instructor training only (Group A)
Number of subjects: 36
Study 15942808 — intervention group
Group type: COMPARATOR
Intervention: Instructor training with self-training (Group B)
Number of subjects: 36
Study 12390373 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous rapidly absorbable suture
Number of subjects: 6566
Study 12390373 — intervention group
Group type: COMPARATOR
Intervention: Continuous slowly absorbable suture
Number of subjects: 6566
Study 12390373 — intervention group
Group type: COMPARATOR
Intervention: Non-absorbable suture
Number of subjects: 6566
Study 12390373 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous sutures
Number of subjects: 6566
Study 12390373 — intervention group
Group type: COMPARATOR
Intervention: Interrupted sutures
Number of subjects: 6566
Study 9554444 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral transmucosal fentanyl citrate (OTFC)
Number of subjects: 92
Study 9554444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 7748519 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol + 1-tyrosine (TY)
Number of subjects: 0
Study 7748519 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol + 1-tryptophan (TP)
Number of subjects: 0
Study 7748519 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol
Number of subjects: 0
Study 7748519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3189959 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (1 mg/kg)
Number of subjects: 6
Study 3189959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 30952736 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus brevis CD2 lozenges
Number of subjects: 75
Study 30952736 — intervention group
Group type: COMPARATOR
Intervention: Sodium bicarbonate mouthwashes (control)
Number of subjects: 75
Study 28077104 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill exercise at 60% of peak oxygen consumption
Number of subjects: 24
Study 28077104 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutter® therapy
Number of subjects: 24
Study 28077104 — intervention group
Group type: COMPARATOR
Intervention: Resting breathing (control)
Number of subjects: 24
Study 26373201 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral zone impression with maxillary denture in-situ
Number of subjects: 12
Study 26373201 — intervention group
Group type: COMPARATOR
Intervention: Neutral zone impression without maxillary denture in-situ
Number of subjects: 12
Study 24016507 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 6520
Study 24016507 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 6520
Study 24016507 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 6520
Study 21347943 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonbranded ads
Number of subjects: 0
Study 21347943 — intervention group
Group type: COMPARATOR
Intervention: Branded ads
Number of subjects: 0
Study 18505215 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealing of margins
Number of subjects: 66
Study 18505215 — intervention group
Group type: EXPERIMENTAL
Intervention: Refurbishing
Number of subjects: 66
Study 18505215 — intervention group
Group type: EXPERIMENTAL
Intervention: Repair
Number of subjects: 66
Study 18505215 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacement
Number of subjects: 66
Study 18505215 — intervention group
Group type: COMPARATOR
Intervention: Untreated
Number of subjects: 66
Study 16275015 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral shoe
Number of subjects: 10
Study 16275015 — intervention group
Group type: COMPARATOR
Intervention: Varus and valgus shoes
Number of subjects: 10
Study 14571005 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg/day) plus subcutaneous nadroparin (4100 units/day)
Number of subjects: 40
Study 14571005 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (325 mg/day)
Number of subjects: 40
Study 10736073 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% propofol plus 0.05% lidocaine at room temperature (20-23 degrees C)
Number of subjects: 70
Study 10736073 — intervention group
Group type: COMPARATOR
Intervention: 1% propofol plus 0.05% lidocaine cooled to 4C
Number of subjects: 70
Study 8737760 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine + Cyclosporine
Number of subjects: 12
Study 8737760 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine alone
Number of subjects: 12
Study 8737760 — intervention group
Group type: COMPARATOR
Intervention: Felodipine alone
Number of subjects: 12
Study 8142113 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene
Number of subjects: 72
Study 8142113 — intervention group
Group type: COMPARATOR
Intervention: Tretinoin
Number of subjects: 72
Study 3728712 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 8
Study 3728712 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose load
Number of subjects: 8
Study 3728712 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 3728712 — intervention group
Group type: EXPERIMENTAL
Intervention: Alimentary odors
Number of subjects: 8
Study 3728712 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonalimentary stimuli
Number of subjects: 8
Study 29605819 — intervention group
Group type: EXPERIMENTAL
Intervention: APIC intervention (weekly 3-hour personalised stimulation sessions for 12 months)
Number of subjects: 376
Study 29605819 — intervention group
Group type: COMPARATOR
Intervention: Control group (publicly funded universal healthcare services)
Number of subjects: 376
Study 26020375 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (10 mg · kg(‐1) · day(‐1) divided every 12 hours) in addition to phototherapy
Number of subjects: 80
Study 26020375 — intervention group
Group type: COMPARATOR
Intervention: Phototherapy alone
Number of subjects: 80
Study 26020375 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid with phototherapy
Number of subjects: 80
Study 25727123 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive depression screens
Number of subjects: 9765
Study 25727123 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonenrollment reasons
Number of subjects: 9765
Study 23828106 — intervention group
Group type: EXPERIMENTAL
Intervention: NeuroFlo catheter treatment
Number of subjects: 100
Study 21401537 — intervention group
Group type: EXPERIMENTAL
Intervention: iResus© application on a smart phone
Number of subjects: 31
Study 21401537 — intervention group
Group type: COMPARATOR
Intervention: Control group (no smart phone)
Number of subjects: 31
Study 19231633 — intervention group
Group type: EXPERIMENTAL
Intervention: A-002 (1-H-indole-3-glyoxamide) 50 mg twice daily
Number of subjects: 393
Study 19231633 — intervention group
Group type: EXPERIMENTAL
Intervention: A-002 (1-H-indole-3-glyoxamide) 100 mg twice daily
Number of subjects: 393
Study 19231633 — intervention group
Group type: EXPERIMENTAL
Intervention: A-002 (1-H-indole-3-glyoxamide) 250 mg twice daily
Number of subjects: 393
Study 19231633 — intervention group
Group type: EXPERIMENTAL
Intervention: A-002 (1-H-indole-3-glyoxamide) 500 mg twice daily
Number of subjects: 393
Study 19231633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 393
Study 17157107 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 microg levonorgestrel (LEV)
Number of subjects: 12
Study 17157107 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 microg norgestimate (NOR)
Number of subjects: 12
Study 12626977 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained inflation with 45 cm H2O continuous positive airway pressure for 30 secs followed by postinflation positive end-expiratory pressure titrated from 20 cm H2O.
Number of subjects: 24
Study 12626977 — intervention group
Group type: EXPERIMENTAL
Intervention: Postinflation positive end-expiratory pressure levels set at 16.7 +/- 2.3 cm H2O in ARDS(p) and 15.6 +/- 2.5 cm H2O in ARDS(exp).
Number of subjects: 24
Study 10742877 — intervention group
Group type: EXPERIMENTAL
Intervention: Family therapy
Number of subjects: 25
Study 10742877 — intervention group
Group type: EXPERIMENTAL
Intervention: Family group psychoeducation
Number of subjects: 25
Study 10742877 — intervention group
Group type: COMPARATOR
Intervention: Family therapy and Family group psychoeducation
Number of subjects: 25
Study 9356569 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation
Number of subjects: 101
Study 8458314 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole + High energy supplement (3.31 MJ daily for 3 months)
Number of subjects: 0
Study 8458314 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (without energy supplementation)
Number of subjects: 0
Study 8458314 — intervention group
Group type: COMPARATOR
Intervention: Standard health care controls
Number of subjects: 0
Study 8458314 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 0
Study 3743091 — intervention group
Group type: EXPERIMENTAL
Intervention: SHEP pilot study recruitment
Number of subjects: 551
Study 29514613 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 29956526 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care provided by community pharmacists in collaboration with diabetologists and diabetes advisors
Number of subjects: 0
Study 23809512 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NMMA (nonselective NO-inhibitor)
Number of subjects: 26
Study 23809512 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 22177399 — intervention group
Group type: EXPERIMENTAL
Intervention: Defusion technique
Number of subjects: 0
Study 22177399 — intervention group
Group type: COMPARATOR
Intervention: Thought suppression technique
Number of subjects: 0
Study 22177399 — intervention group
Group type: COMPARATOR
Intervention: Control group (no instruction)
Number of subjects: 0
Study 20883502 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentax Airway Scope
Number of subjects: 400
Study 20883502 — intervention group
Group type: COMPARATOR
Intervention: C-MAC
Number of subjects: 400
Study 18693151 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus johnsonii (La1) supplementation
Number of subjects: 54
Study 18693151 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 15783030 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux‐Y duodenojejunal anastomosis (RY‐DJ)
Number of subjects: 20
Study 15783030 — intervention group
Group type: COMPARATOR
Intervention: Roux‐Y choledochojejunostomy (R‐Y)
Number of subjects: 20
Study 12051214 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard textual patient information leaflet (PIL)
Number of subjects: 196
Study 12051214 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate-form patient information leaflet with icons and graphs
Number of subjects: 196
Study 12051214 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothetical pain medication information leaflet
Number of subjects: 196
Study 12051214 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional PIL)
Number of subjects: 196
Study 10588565 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (15 mL 2.5 mg/mL) every 4 hours for 48 hours via catheter
Number of subjects: 41
Study 10588565 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo) every 4 hours for 48 hours via catheter
Number of subjects: 41
Study 9119355 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (radiotherapy followed by melphalan and prednisone every 6 weeks for 3 years)
Number of subjects: 53
Study 9119355 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (4000 to 5000 cGy)
Number of subjects: 53
Study 1546839 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine challenge test (maximum dose of 12.25 mumol)
Number of subjects: 225
Study 1546839 — intervention group
Group type: EXPERIMENTAL
Intervention: PEF variability (measured as mean daily maximum amplitude as a percentage of the mean)
Number of subjects: 225
Study 1546839 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial reactivity
Number of subjects: 225
Study 1546839 — intervention group
Group type: EXPERIMENTAL
Intervention: Both bronchial reactivity and PEF variability
Number of subjects: 225
Study 2866784 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam (20 mg)
Number of subjects: 8
Study 2866784 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrazepam (10 mg)
Number of subjects: 8
Study 2866784 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 29990271 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel lightweight incremental quantile estimator
Number of subjects: 0
Study 29990271 — intervention group
Group type: EXPERIMENTAL
Intervention: Deterministic updates with adjusted step size
Number of subjects: 0
Study 29990271 — intervention group
Group type: EXPERIMENTAL
Intervention: Single parameter tuning
Number of subjects: 0
Study 29990271 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiplicative algorithm
Number of subjects: 0
Study 30244217 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intravenous infusion of tocilizumab
Number of subjects: 50
Study 30244217 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 50
Study 27037462 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-interval misoprostol (2 tablets of 400 μg at 12 hours and 2 placebo tablets at 3 hours before procedure)
Number of subjects: 120
Study 27037462 — intervention group
Group type: COMPARATOR
Intervention: Short-interval misoprostol (2 placebo tablets at 12 hours and 2 tablets of 400 μg at 3 hours before procedure)
Number of subjects: 120
Study 27037462 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-interval misoprostol
Number of subjects: 120
Study 27037462 — intervention group
Group type: COMPARATOR
Intervention: Short-interval misoprostol
Number of subjects: 120
Study 24871547 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 41
Study 24871547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 22930699 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 23 mg/d
Number of subjects: 0
Study 20662877 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS at 3 pps
Number of subjects: 35
Study 20662877 — intervention group
Group type: COMPARATOR
Intervention: TENS at 80 pps
Number of subjects: 35
Study 18569681 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficult divided attention task during learning and test phases (Experiment 1)
Number of subjects: 0
Study 18569681 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulated encoding time and collected remember-know judgements (Experiment 2)
Number of subjects: 0
Study 16145024 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based CME intervention
Number of subjects: 97
Study 16145024 — intervention group
Group type: COMPARATOR
Intervention: Live, small-group, interactive CME workshop
Number of subjects: 97
Study 11810088 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (50 microg, repeated every 4 hours to a maximum of 5 doses)
Number of subjects: 100
Study 11810088 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol
Number of subjects: 100
Study 11810088 — intervention group
Group type: COMPARATOR
Intervention: Oral misoprostol (50 microg, repeated every 4 hours to a maximum of 5 doses)
Number of subjects: 100
Study 11810088 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 10513854 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (mean dose = 24.5 mg/day)
Number of subjects: 40
Study 10513854 — intervention group
Group type: COMPARATOR
Intervention: Nortriptyline (mean dose = 51.3 mg/day; mean blood level = 85.5 ng/mL)
Number of subjects: 40
Study 7491235 — intervention group
Group type: EXPERIMENTAL
Intervention: RRV-S1 vaccine (4 x 10(4) plaque-forming units)
Number of subjects: 989
Study 7491235 — intervention group
Group type: EXPERIMENTAL
Intervention: RRV-TV vaccine (4 x 10(4) plaque-forming units)
Number of subjects: 989
Study 7491235 — intervention group
Group type: EXPERIMENTAL
Intervention: RRV-S1 vaccine
Number of subjects: 989
Study 7491235 — intervention group
Group type: EXPERIMENTAL
Intervention: RRV-TV vaccine
Number of subjects: 989
Study 7491235 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 989
Study 1834395 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release disopyramide (400 mg/day)
Number of subjects: 12
Study 1834395 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release disopyramide (500 mg/day)
Number of subjects: 12
Study 6344610 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental diet (65% carbohydrate, 20% fat, 15% protein for 6 weeks)
Number of subjects: 6
Study 6344610 — intervention group
Group type: COMPARATOR
Intervention: Control diet (45% carbohydrate, 40% fat, 15% protein for 4 weeks)
Number of subjects: 6
Study 31778458 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 times/week training (EG1)
Number of subjects: 40
Study 31778458 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 times/week training (EG2)
Number of subjects: 40
Study 31778458 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 40
Study 28888358 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year extension of early intervention (EI)
Number of subjects: 160
Study 28888358 — intervention group
Group type: COMPARATOR
Intervention: step-down psychiatric care
Number of subjects: 160
Study 25350500 — intervention group
Group type: EXPERIMENTAL
Intervention: Burdock root tea (3 cups daily, each cup containing 2 g/150 mL boiled water)
Number of subjects: 36
Study 25350500 — intervention group
Group type: COMPARATOR
Intervention: Control group (3 cups of 150 cc boiled water daily)
Number of subjects: 36
Study 25707081 — intervention group
Group type: EXPERIMENTAL
Intervention: Chew 2 pieces of sugar-free gum for 20 minutes, 3x per day
Number of subjects: 177
Study 25707081 — intervention group
Group type: EXPERIMENTAL
Intervention: Chew 2 pieces of sugar-free gum for 12 minutes, 5x per day
Number of subjects: 177
Study 25707081 — intervention group
Group type: COMPARATOR
Intervention: No gum
Number of subjects: 177
Study 23236367 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose albendazole during pregnancy
Number of subjects: 2016
Study 23236367 — intervention group
Group type: EXPERIMENTAL
Intervention: Quarterly single-dose albendazole during childhood
Number of subjects: 2016
Study 23236367 — intervention group
Group type: COMPARATOR
Intervention: Placebo during pregnancy
Number of subjects: 2016
Study 23236367 — intervention group
Group type: COMPARATOR
Intervention: Placebo during childhood
Number of subjects: 2016
Study 20411695 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep restriction therapy plus hypnotic withdrawal (SR+HW)
Number of subjects: 46
Study 20411695 — intervention group
Group type: COMPARATOR
Intervention: Sleep hygiene education (SHE)
Number of subjects: 46